The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Combination nab-paclitaxel (Nab-P) plus gemcitabine (G) as first-line treatment in advanced pancreatic cancer (APC): Our experience.
Fernando De Vita
No relevant relationships to disclose
Michele Orditura
No relevant relationships to disclose
Antonio Febbraro
No relevant relationships to disclose
Floriana Morgillo
No relevant relationships to disclose
Maria Maddalena Laterza
No relevant relationships to disclose
Alessio Fabozzi
No relevant relationships to disclose
Guido Giordano
No relevant relationships to disclose
Beatrice Savastano
No relevant relationships to disclose
Angelica Petrillo
No relevant relationships to disclose
Jole Ventriglia
No relevant relationships to disclose
Fortunato Ciardiello
No relevant relationships to disclose